N-((S)-3-{2-ethyl-4-[5-(2-isobutyl-6-methoxy-pyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-((S)-3-{2-ethyl-4-[5-(2-isobutyl-6-methoxy-pyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide
• 英文别名: N-((S)-3-{2-Ethyl-4-[5-(2-isobutyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide；N-((S)-3-{2-ethyl-4-[5-(2-isobutyl-6-methoxypyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-6-methylphenoxy}-2-hydroxypropyl)-2-hydroxyacetamide；N-((S)-3-{2-ethyl-4-[5-(2-isobutyl-6-methoxypyridin-4-yl)[1,2,4]oxadiazol-3-yl]-6-methylphenoxy}-2-hydroxypropyl)-2-hydroxyacetamide；N-[(2S)-3-[2-ethyl-4-[5-[2-methoxy-6-(2-methylpropyl)pyridin-4-yl]-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide
• 化学式: C₂₆H₃₄N₄O₆
• 分子量: 498.579
• InChiKey: GZPOHEFIDDZOCD-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  140
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-ethyl-4,N-dihydroxy-5-methylbenzamidine 在 氨 、 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 47.08h， 生成 N-((S)-3-{2-ethyl-4-[5-(2-isobutyl-6-methoxy-pyridin-4-yl)-1,2,4-oxadiazol-3-yl]-6-methyl-phenoxy}-2-hydroxy-propyl)-2-hydroxy-acetamide
  参考文献：
  名称：

  Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines

  摘要：

  In a previous communication we reported on the discovery of aminopyridine 1 as a potent, selective and orally active S1P(1) receptor agonist. More detailed studies revealed that this compound is phototoxic in vitro. As a result of efforts aiming at eliminating this undesired property, a series of alkoxy substituted pyridine derivatives was discovered. The photo irritancy factor (PIF) of these alkoxy pyridines was significantly lower than the one of aminopyridine 1 and most compounds were not phototoxic. Focused SAR studies showed, that 2-, 3-, and 4-pyridine derivatives delivered highly potent S1P(1) receptor agonists. While the 2-pyridines were clearly more selective against S1PR(3), the corresponding 3- or 4 pyridine analogues showed significantly longer oral half-lives and as a consequence longer pharmacological duration of action after oral administration. One of the best compounds, cyclopentoxy-pyridine 45b lacked phototoxicity, showed EC50 values of 0.7 and 140 nM on S1PR(1) and S1PR(3), respectively, and maximally reduced the blood lymphocyte count for at least 24 h after oral administration of 10 mg/kg to Wistar rats. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.03.020

文献信息

• Pyridin-4-yl derivatives as immunomodulating agents
  申请人：Bolli Martin

  公开号：US20100063108A1

  公开（公告）日：2010-03-11

  The invention relates to pyridine derivatives of Formula (I) wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及公式（I）中的吡啶衍生物，其中A、R1、R2、R3、R4、R5和R6如描述中所述，它们的制备以及它们作为药用活性化合物的用途。所述化合物特别作为免疫调节剂。
• PYRIDIN-4-YL DERIVATIVES
  申请人：Bolli Martin

  公开号：US20120108638A1

  公开（公告）日：2012-05-03

  The invention relates to pyridine derivatives of Formula (I), wherein A, R 1 , R 2 , R 3 , and R 4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及式（I）的吡啶衍生物，其中A、R1、R2、R3和R4如描述中所述，它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
• PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2069336A1

  公开（公告）日：2009-06-17
• US8580824B2
  申请人：——

  公开号：US8580824B2

  公开（公告）日：2013-11-12
• US8658675B2
  申请人：——

  公开号：US8658675B2

  公开（公告）日：2014-02-25